SCHEMBL1491014

SCHEMBL1491014

O=C(Nc1csc(-c2ccc(Cl)cc2)c1C(=O)O)OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
GAA P10253 2/20 0.45
PPARA Q07869 1/20 0.44
MGLL Q99685 2/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
TRPV1 Q8NER1 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PTPN1 P18031 1/20 0.43
CASP3 P42574 2/20 0.42
KAT2B Q92831 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490651 0.90 NPC1 (0.48) HDAC3HDAC1HDAC2NPC1RAB9A
SCHEMBL12756642 0.88 HDAC3 (0.50) HDAC3HDAC1HDAC2NPC1RAB9A
SCHEMBL12756644 0.88 MEN1 (0.45) HDAC3HDAC1HDAC2NPC1RAB9A
SCHEMBL12756643 0.86 TDP1 (0.41) HDAC3HDAC1HDAC2GAAPPARA
SCHEMBL12756632 0.83 LMNA (0.50) POLBMEN1KMT2ASMN1; SMN2
SCHEMBL12756648 0.83 HDAC1 (0.52) HDAC3HDAC1HDAC2NPC1RAB9A
SCHEMBL12830003 0.81 TP53 (0.49) GAAPOLBMAPTCYP1A2CYP2D6
SCHEMBL1490241 0.81 ALOX15 (0.53) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL1954635 0.81 ANO1 (0.60) MEN1KMT2ASMN1; SMN2
SCHEMBL12830007 0.80 CNR1 (0.57) NPC1RAB9AMAPTCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 US disclosed
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 US disclosed
EP-2477982-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2012-07-25 EP disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 WO disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 US disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 HDAC3 1653/4885HDAC1 2696/4885HDAC2 2333/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 HDAC3 1653/4885HDAC1 2696/4885HDAC2 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.